Why I Keep Buying These 14 Incredible Growth Stocks

In This Article:

Investing in individual growth stocks can be a rollercoaster ride, but the potential rewards can be substantial. Since the 2008 financial crisis, numerous growth stocks have significantly outperformed passive index funds.

Some standout performers have even delivered returns exceeding 1,000% in less than five years. Nvidia (NASDAQ: NVDA), the chipmaker at the heart of the artificial intelligence (AI) revolution, exemplifies this potential, turning a $10,000 investment into nearly $300,000 over the past 60 months.

NVDA Total Return Level Chart
NVDA Total Return Level Chart

My tax-advantaged portfolios include 14 stocks primarily held for their growth prospects. While some of these growth stocks pay dividends, that's not the main reason for owning them.

Here, I'll explain why I continue to invest in each of these companies and discuss their 12-month upside potential based on Wall Street's consensus price targets and year-to-date performance.

A hand drawing a growth curve.
Image Source: Getty Images.

Archer Aviation: Pioneering electric air taxis

Archer Aviation (NYSE: ACHR) is at the forefront of the electric vertical takeoff and landing (eVTOL) aircraft industry. The company aims to revolutionize urban transportation with its electric air taxis, potentially disrupting the $1 trillion global urban air mobility market.

Wall Street's consensus suggests a 209% upside potential for Archer Aviation, highlighting its promising long-term growth prospects despite a negative 49.8% year-to-date performance. The company's progress in aircraft development and strategic partnerships with major airlines bolster its potential for future success.

Aspen Aerogels: Innovating in high-performance insulation

Aspen Aerogels (NYSE: ASPN) develops advanced aerogel insulation materials for various industries, including electric vehicles, energy infrastructure, and sustainable building materials. The company's products offer superior thermal performance and energy efficiency.

Aspen Aerogels has outperformed the S&P 500 with a 44.2% year-to-date gain in 2024. The 43.8% upside potential projected by analysts over the next 12 months stems from the growing demand for high-performance insulation materials across multiple industries.

CRISPR Therapeutics: Pioneering gene-editing therapies

CRISPR Therapeutics (NASDAQ: CRSP) is at the forefront of developing gene-editing therapies for serious diseases. Fewer than 12 months ago, the company achieved a major milestone with the approval of Casgevy, its groundbreaking treatment for sickle cell disease and beta-thalassemia, developed in partnership with Vertex Pharmaceuticals.

Wall Street projections indicate a 72% upside for CRISPR Therapeutics over the next 12 months despite a negative 23.6% year-to-date performance. Along with the company's robust pipeline, the recent approval of Casgevy, the first CRISPR-based therapy to reach the market, could drive significant long-term growth.